OBJECTIVES: We assessed the efficacy and safety of two a1-adrenoceptor antagonists, @entity9940 and @entity6731 , in the treatment of male lower urinary tract symptoms. METHODS: @entity1 aged 50 years or older who had a total International Prostate Symptom Score (IPSS) of 8 or higher were enrolled in this study. Forty-six @entity1 were randomized into two groups. Twenty-three @entity1 were initially prescribed @entity9940 0.2 mg once daily for 3 months, followed by @entity6731 4 mg twice daily for 3 months (group T); the other group of 23 @entity1 were initially prescribed @entity6731 , followed by @entity9940 (group S). @entity1 then switched to the alternative treatment after a 1-month clearance period. Evaluations included clinical determination of IPSS, quality-of-life index, maximum flow rate and postvoid residual urine volume before and after treatment. RESULTS: A total of 46 @entity1 , 23 in group T and 23 in group S, were treated and 41 (89.1%) completed the treatment. IPSS, quality-of-life index, maximum flow rate and postvoid residual urine volume were significantly improved in both groups after treatment. The changes in the total IPSS from baseline in groups S and T at 3 months were -6.6 and -7.5, respectively. There were no significant differences between the two groups. After taking both medications, 18 @entity1 preferred @entity6731 , 11 preferred @entity9940 and others felt they had the same effects. Six and none @entity1 experienced adverse events during @entity6731 and @entity9940 treatment, respectively. CONCLUSION: Two types of a1-adrenoceptor antagonists in the same individuals provide similar efficacy. Profiles and difference of each drug should be considered in making treatment choice.

Comparison of Two Different a1-Adrenoceptor Antagonists, @entity9940 and XXXX , in the Treatment of Male Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective Randomized Crossover Study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Men', 'men'] @entity6731 :: ('MESH:C095285', 'Chemical') :: ['silodosin'] @entity9940 :: ('MESH:C088482', 'Chemical') :: ['tamsulosin']
@entity6731 :: (MESH:C095285,Chemical) :: ['Silodosin']
